I'm LongbridgeAI, I can summarize articles.Nasus Pharma has appointed Brendan P. O’Grady as CEO, effective July 27, 2026, succeeding Dan Teleman. O’Grady brings extensive experience from Teva and Assertio Holdings. His initial focus includes commercial planning for NS002, pipeline advancement, and business development leveraging the Nasax platform. NS002 is scheduled to enter pivotal trials in Q4 2026, with top-line data expected in Q1 2027.
- Nasus Pharma named Brendan P. O’Grady chief executive officer, effective July 27, 2026, replacing Dan Teleman. * O’Grady previously spent 21 years at Teva, including CEO of Teva USA, later served as CEO of Assertio Holdings. * Initial priorities include commercial planning for NS002, pipeline advancement, business development, supported by the Nasax intranasal platform. * NS002 is slated to enter a pivotal trial in Q4 2026, with topline data expected in Q1 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here